PMID- 16979146
OWN - NLM
STAT- MEDLINE
DCOM- 20070123
LR  - 20220309
IS  - 0006-8993 (Print)
IS  - 0006-8993 (Linking)
VI  - 1118
IP  - 1
DP  - 2006 Nov 6
TI  - Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram 
      response in major depressive disorder.
PG  - 176-82
AB  - The brain-derived neurotrophic factor (BDNF) gene is a candidate gene for 
      influencing the clinical response to treatment with antidepressants. The purpose 
      of this study was to determine the relationship between the Val66Met polymorphism 
      in the BNDF gene and the response to citalopram in a Korean population with major 
      depressive disorder (MDD). Citalopram was administered for 8 weeks to the 83 
      patients who completed this study. We found that the genotype, allele, and 
      allele-carrier distributions for the Val66Met polymorphism differed significantly 
      between responders (Rp) and nonresponders (Non-Rp). The frequency of M-allele 
      carriers (VM+MM) was higher in Rp than in Non-Rp (chi(2)=8.926, p=0.003, 
      OR=4.375, 95%CI=1.609-11.892), as was the M-allele frequency (chi(2)=6.879, 
      p=0.009, OR=2.500, 95%CI=1.249-5.005). There were also significant differences in 
      the core (p=0.012) and activity (p=0.008) scores. Patients carrying the M-allele 
      had a lower score. Also, patients carrying the M-allele tended to have lower 
      psychic anxiety (p=0.072). The percentage change in the total HAM-D score was 
      higher for M-allele carriers (VM+MM allele) than for noncarriers (p=0.034) after 
      8 weeks of medication. We found that the genotype, allele, and allele-carrier 
      distributions did not differ significantly between MDD patients and normal 
      controls. These results suggest that the Val66Met polymorphism of BDNF is 
      associated with citalopram efficacy, with M-allele carriers responding better to 
      citalopram treatment. Moreover, the Val66Met polymorphism was correlated with 
      improvements in core, activity, and psychic anxiety symptoms.
FAU - Choi, Myoung-Jin
AU  - Choi MJ
AD  - Depression Center, Korea University, Seoul, Republic of Korea.
FAU - Kang, Rhee-Hun
AU  - Kang RH
FAU - Lim, Se-Won
AU  - Lim SW
FAU - Oh, Kang-Seob
AU  - Oh KS
FAU - Lee, Min-Soo
AU  - Lee MS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060918
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0DHU5B8D6V (Citalopram)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amino Acid Substitution/genetics
MH  - Antidepressive Agents, Second-Generation/pharmacology
MH  - Anxiety Disorders/genetics/metabolism/physiopathology
MH  - Brain/drug effects/metabolism/physiopathology
MH  - Brain Chemistry/drug effects/genetics
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Citalopram/*pharmacology
MH  - DNA Mutational Analysis
MH  - Depressive Disorder, Major/*drug therapy/*genetics/metabolism
MH  - Drug Resistance/*genetics
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease/genetics
MH  - Genetic Testing
MH  - Genotype
MH  - Heterozygote
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Point Mutation/genetics
MH  - Polymorphism, Genetic/*genetics
EDAT- 2006/09/19 09:00
MHDA- 2007/01/24 09:00
CRDT- 2006/09/19 09:00
PHST- 2005/12/23 00:00 [received]
PHST- 2006/06/23 00:00 [revised]
PHST- 2006/08/04 00:00 [accepted]
PHST- 2006/09/19 09:00 [pubmed]
PHST- 2007/01/24 09:00 [medline]
PHST- 2006/09/19 09:00 [entrez]
AID - S0006-8993(06)02367-5 [pii]
AID - 10.1016/j.brainres.2006.08.012 [doi]
PST - ppublish
SO  - Brain Res. 2006 Nov 6;1118(1):176-82. doi: 10.1016/j.brainres.2006.08.012. Epub 
      2006 Sep 18.